Navigation Links
WuXi PharmaTech Announces First-Quarter 2011 Results
Date:5/10/2011

Cautionary Note Regarding Forward-Looking StatementsStatements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, our financial guidance for second-quarter and full-year 2011 (including, as applicable, estimated total net revenues, China-based Laboratory Services net revenues, U.S.-based Laboratory Services net revenue, Manufacturing Services net revenues, operating margins, capital expenditures, effective tax rates, and other trends), expanded growth in our commercial manufacturing business, our planned investments for 2011, anticipated industry changes and trends and our ability to benefit therefrom.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, the state of the global economy may continue to be uncertain; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced and offshored R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis; these investments may not yield the desired results and we may need to modify the nature and level of our investments and capita
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Pa. , May 21, 2013  Lehigh Valley ... TRU-D SmartUVC TM devices, adding to its existing ... seven devices taking up residence within the network, LVHN ... the U.S. to proactively combat superbugs and provide the ... for Total Room Ultraviolet Disinfector, TRU-D – the signature ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... , , SOUTHFIELD, Mich. ... ., (Nasdaq: TEAM ), a worldwide provider of information ... it has named Guido Roumans as director of global life ... management and ongoing capability enhancement in support of TechTeam,s life ...
... , MUMBAI, India , Feb. 9 ... a presence in India , Western and Central Eastern ... alliance with DreamCIS Inc., a leading CRO based in ... decade of experience in offering clinical research services to pharmaceutical ...
Cached Medicine Technology:TechTeam Global Appoints Life Sciences Services Director 2TechTeam Global Appoints Life Sciences Services Director 3SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 2SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 3
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, a ... injured by defective medical devices, is offering remarks on the ... the Estate of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, ... May 21, 2013, Bloomberg report noted that the ... a “car dealership” in how it deployed its strategy to ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Global Proving Ground (GPG), a fast rising ... retailer of health and fitness supplements, are partnering up ... Island. “We cast the show by having millions ... our unique social networking platform,” states show’s creator James ... an island in the Pacific Ocean, where they must ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... disparities in cost-effectiveness analysis, would allow policy makers ... reduce disparities between racial ethnic subgroups, and be ... in the Journal of the National ... be used to identify effective and cost-effective strategies ...
... , TUESDAY, Sept. 6 (HealthDay News) -- Breast ... much better response to neoadjuvant chemotherapy -- chemo given ... patients, a new study finds. U.S. researchers looked ... who underwent neoadjuvant chemotherapy. Complete pathological response (pCR) ...
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) -- ... ibuprofen during the first stage of their pregnancy may ... "We,re seeing a 2.4-fold increased risk in ... said Anick Berard, senior author of a paper published ...
... An innovative approach to treating neonatal feeding problems at ... to feed orally to be discharged earlier and without ... According to American Academy of Pediatrics guidelines, ... the hospital, they must establish safe oral feeding methods. ...
... in German . The stomach bacterium Helicobacter ... development of gastric cancer, the third most common cause of cancer-related ... have now identified a mechanism of Helicobacter pylori that damages the ... for malignant transformation. Gastric cancer is one of the most ...
... been prescribing codeine for postpartum pain management for many years, ... taking the opioid. But the death of an infant ... providers questioning the safety of the drug when used by ... have begun the practice of prescribing oxycodone as an alternative ...
Cached Medicine News:Health News:Modeling disparities may help with cervical cancer prevention 2Health News:Going Straight to Chemo May Be Better for Certain Breast Cancers 2Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: